Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
2009 · Clinical Cancer Research · 483 citations
https://doi.org/10.1158/1078-0432.ccr-08-2132
M
Mohammed A. Aleskandarany
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
87
Papers
4.4K
Citations
40
h-index
77
i10-index
Mohammed A. Aleskandarany is an academic researcher from Nottingham University Hospitals NHS Trust. The author has contributed to research in topics: Breast Cancer Treatment Studies & Cancer Cells and Metastasis & Cancer-related Molecular Pathways. The author has an h-index of 40, co-authored 74 publications.
ORCID: 0000-0001-5538-5946Papers by this author
worksPrognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
2012 · Breast Cancer Research · 126 citations
https://doi.org/10.1186/bcr3084
MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
2016 · British Journal of Cancer · 124 citations
https://doi.org/10.1038/bjc.2016.46
Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study
2014 · Breast Cancer Research and Treatment · 61 citations
https://doi.org/10.1007/s10549-014-2927-5
Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers
2017 · Cancer Immunology Research · 60 citations
https://doi.org/10.1158/2326-6066.cir-16-0195
DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
2015 · Breast Cancer Research and Treatment · 58 citations
https://doi.org/10.1007/s10549-015-3306-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat